Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial-Reference-Cited by-同舟云学术

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial

Published:2023-02 Issue:2 Volume:23 Page:233-246
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Platt Heather,Omole Tosin,Cardona Jose,Fraser Neil J,Mularski Richard A,Andrews Charles,Daboul Nizar,Gallagher Nancy,Sapre Aditi,Li Jianing,Polis Adam,Fernsler Doreen,Tamms Gretchen,Xu Weifeng,Murphy Rocio,Skinner Julie,Joyce Joseph,Musey Luwy

Funder

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference26 articles.

1. Pneumococcal infection in adults: burden of disease;Drijkoningen;Clin Microbiol Infect,2014

2. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15;Wahl;Lancet Glob Health,2018

3. Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world;Cui;Hum Vaccin Immunother,2017

4. Non-invasive pneumococcal pneumonia due to vaccine serotypes: a systematic review and meta-analysis;Lansbury;EClinicalMedicine,2022

5. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence;Niederman;Expert Rev Vaccines,2021

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024;MMWR. Morbidity and Mortality Weekly Report;2024-09-12

2. Aktuelle und neue Impfstoffe gegen Pneumokokken;Die Innere Medizin;2024-09-02

3. New Vaccines for Chronic Respiratory Patients;Archivos de Bronconeumología;2024-09

4. Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023);Journal of Infection;2024-08

5. A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6);Clinical Infectious Diseases;2024-07-31